Methylpheni Tad

Methylphenidate, the active ingredient in Methylpheni Tad, is a central nervous system stimulant presented as an oral formulation for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylpheni Tad as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is indicated for conditions within the central nervous system stimulant therapeutic area.

- Attention deficit hyperactivity disorder (ADHD): Improves concentration, reduces hyperactivity and impulsivity in patients. - Narcolepsy: Decreases daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Loss of appetite: reduced desire to eat. - Headache: mild to moderate cranial pain. - Stomach ache: abdominal discomfort or pain. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychiatric symptoms: severe anxiety, agitation, or hallucinations. - Growth suppression: reduced height velocity in children. - Tics: sudden, repetitive, non‑rhythmic movements.

When prescribing methylphenidate, clinicians should observe several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate heart history and blood pressure before initiation. - Psychiatric evaluation: screen for prior psychosis, bipolar disorder, or severe anxiety. - Growth monitoring: regularly measure height and weight in pediatric patients. - Drug abuse potential: consider risk of dependence, especially in individuals with substance‑use history. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can reduce blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may enhance serotonergic activity. - Antacids: may affect absorption; monitor therapeutic response. - CYP2D6 inhibitors: can increase methylphenidate plasma levels.